Status and timing of angiotensin receptor–neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry

Davide Stolfo; Lina Benson; Felix Lindberg; Ulf Dahlström; Oskar Käck; Gianfranco Sinagra; Lars H. Lund; Gianluigi Savarese

doi:10.1002/ejhf.3404

July 30, 2024European Journal of Heart FailureOpen Access

Status and timing of angiotensin receptor–neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry

View Full Paper

Ask AI

Bookmark

Share

Key Points

Initiation of angiotensin receptor-neprilysin inhibitors in heart failure with reduced ejection fraction shows variation across settings, indicating gaps in treatment.
Key evidence from the Swedish Heart Failure Registry reveals specific predictors of ARNI initiation, emphasizing patient demographics.
Exploration of timing and predictors involved observational analysis in a large nationwide cohort of heart failure patients with reduced ejection fraction across diverse clinical settings. Highlights the need to improve timely treatment in this population.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Analysis uncovers factors influencing ARNI initiation in heart failure patients, suggesting areas for improvement in treatment timing.

Abstract

We explored timing, settings and predictors of angiotensin receptor-neprilysin inhibitor (ARNI) initiation in a large, nationwide cohort of patients with heart failure (HF) with reduced ejection fraction (HFrEF).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stolfo et al. (2024) studied this question.

synapsesocial.com/papers/68e5e6f9b6db64358757bead https://doi.org/10.1002/ejhf.3404

View Full Paper

Ask AI

Bookmark

Share

Status and timing of angiotensin receptor–neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Status and timing of angiotensin receptor–neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading